On Wednesday, Shares of Old Republic International Corporation (NYSE:ORI), gained 1.04% to $16.54.
Old Republic International Corporation, stated that net operating income for this year’s second quarter and first half exceeded our expectations. The results were bolstered by much improved underwriting performance in the Company’s general insurance business and by continued strength of its title insurance operations. The RFIG run-off segment also posted better year-over-year results partly due to less burdensome litigation claim expense provisions than practiced in the same periods of 2014. This year’s merged net income was comparatively lower as the unusually high level of realized investment gains recognized in the first half of 2014 were not repeated in this year’s second quarter and year-to-date periods.
Old Republic International Corporation, through its auxiliaries, engages in the insurance underwriting and related services business primarily in the United States and Canada. The company’s General Insurance Group segment offers automobile extended warranty, aviation, commercial automobile, commercial multi-peril, general liability, home warranty, inland marine, travel accident, and workers’ compensation insurance products; and financial indemnity products for specialty coverages, counting errors and omissions, directors and officers, fidelity, guaranteed asset protection, and surety.
Shares of Arena Pharmaceuticals, Inc. (NASDAQ:ARNA), inclined 0.25% to $4.09, during its last trading session.
Arena Pharmaceuticals, declared the initiation of patient screening in a Phase 2 proof-of-concept clinical trial of APD334 in ulcerative colitis. Discovered by Arena, APD334 is an oral, investigational, Sphingosine 1-Phosphate Subtype 1 (S1P1) receptor modulator with therapeutic potential in ulcerative colitis in addition to other autoimmune diseases.
“Important aims of pharmacotherapy for ulcerative colitis are to induce and maintain remission while improving the patient’s quality of life, and, based on the results from our Phase 1 program, we believe APD334 has the potential to achieve these aims,” said Jack Lief, Arena’s President and Chief Executive Officer. “In addition to ulcerative colitis, we believe APD334 could have utility for a variety of autoimmune diseases.”
Arena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes novel drugs that target G protein-coupled receptors. The company offers BELVIQ, a drug used to treat chronic weight administration in adults.
At the end of Wednesday’s trade, Shares of Perrigo Company plc Ordinary Shares (NYSE:PRGO), gained 0.40% to $192.83.
Mylan N.V., declared that it received regulatory clearance from the European Commission under the European Union Merger Regulation (EUMR) for its projected acquisition of Perrigo Company plc (NYSE: PRGO; TASE).
Mylan’s Executive Chairman Robert J. Coury commented, “Recently marks yet another important milestone in the process of concluding our acquisition of Perrigo and serves as further affirmation of the sound industrial logic of this compelling combination. We look forward to ongoing on this path and concluding the transaction in the coming months.”
Perrigo Company plc, through its auxiliaries, develops, manufactures, and distributes over-the-counter (OTC) and generic prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API).
Finally, Air Products & Chemicals, Inc. (NYSE:APD), ended its last trade with 0.99% gain, and closed at $134.14.
Air Products, declared the addition of Charles “Casey” Cogut, Senior M&A Counsel at the law firm Simpson Thacher & Bartlett LLP (STB), to its board of directors.
“Mr. Cogut is one of the most prominent and well known corporate lawyers in America, and has been a sought-after advisor by the boards of many companies. I am very happy to welcome him to our company’s board of directors. He has extensive experience, has been involved in some of the largest merger and acquisition transactions in the last 30 years, and brings with him a wealth of knowledge and experience that we presently do not have on our board,” said Seifi Ghasemi, Air Products’ chairman, president and chief executive officer.
Air Products and Chemicals, Inc. provides atmospheric gases, process and specialty gases, performance materials, equipment, and services worldwide. The company operates in Merchant Gases, Tonnage Gases, Electronics and Performance Materials, and Equipment and Energy segments.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
